Form 4: Cidara Therapeutics Director Ryan Spencer Granted Stock Options

Cidara Therapeutics, Inc. Director Ryan Spencer was granted 11,100 stock options with an exercise price of $21.31, vesting by June 2026.

Summary

• Ryan Spencer, a Director of Cidara Therapeutics, Inc. (CDTX), acquired 11,100 stock options.
• The options have an exercise price of $21.31 per share.
• The shares subject to the option will vest on the earlier of June 18, 2026, or the day prior to the Issuer's 2026 annual meeting of stockholders.
• The expiration date for these stock options is June 17, 2035.
• Following this transaction, Mr. Spencer beneficially owns 11,100 derivative securities (stock options).

Sentiment

Score: 6

Explanation: The document reports a routine insider transaction related to director compensation. It is a neutral event with a slight positive tilt due to the alignment of interests, but does not convey significant new operational or financial performance information.

Positives

• The grant of stock options aligns the director's financial interests with those of the shareholders, incentivizing long-term company performance.
• Equity compensation is a standard practice to attract and retain qualified board members.

Risks

• The value of the stock options is dependent on the future market price of Cidara Therapeutics' common stock; if the stock price does not exceed the exercise price, the options may expire worthless.
• Dilution risk to existing shareholders if and when these options are exercised and new shares are issued.

Future Outlook

The vesting schedule of the stock options, extending to June 2026 or the 2026 annual meeting, indicates a long-term incentive structure for the director, aligning their future interests with the company's performance.

Industry Context

The grant of stock options to directors is a common form of equity compensation within the biotechnology and pharmaceutical industries, used to align the interests of board members with the long-term success of the company and its shareholders.

Comparison to Industry Standards

• The grant of stock options as a component of director compensation is a standard practice across publicly traded companies, particularly in growth-oriented sectors like biotechnology.
• Without specific details on Cidara Therapeutics' overall compensation philosophy or peer group compensation data, a direct quantitative comparison to industry benchmarks for director equity grants is not feasible from this document alone.

Corporate Governance

Related Party Transactions

• The grant of stock options to Ryan Spencer, a Director of Cidara Therapeutics, Inc., constitutes a related party transaction as it involves compensation provided by the company to a member of its board of directors. This is a standard and disclosed form of compensation.

Stakeholder Impact

• Shareholders: The grant aims to align the director's interests with long-term shareholder value creation. Potential for minor dilution upon exercise of options.
• Employees: No direct impact on general employees mentioned in this filing.

Next Steps

• The stock options will vest according to the specified schedule (earlier of June 18, 2026, or the day prior to the 2026 annual meeting).
• The director may choose to exercise the options at any time after vesting and before the expiration date of June 17, 2035, assuming the stock price is favorable.

Key Dates

Keywords

Cidara Therapeutics, CDTX, Stock Option, Form 4, Insider Transaction, Director Compensation, Equity Grant, Beneficial Ownership